L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum

[1]  R. Moratalla,et al.  Dopamine D3 Receptor Modulates l‐DOPA‐Induced Dyskinesia by Targeting D1 Receptor‐Mediated Striatal Signaling , 2015, Cerebral cortex.

[2]  Qin Li,et al.  Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. , 2015, Cerebral cortex.

[3]  R. Moratalla,et al.  Dopaminergic regulation of olfactory type G‐protein α subunit expression in the striatum , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  Hongbin Sun,et al.  Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson’s disease , 2015, Journal of Neural Transmission.

[5]  M. Casarejos,et al.  Optimal excitation and emission wavelengths to analyze amino acids and optimize neurotransmitters quantification using precolumn OPA-derivatization by HPLC , 2015, Amino Acids.

[6]  S. Hitchcock,et al.  Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia , 2015, Neurobiology of Disease.

[7]  R. Moratalla,et al.  Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice , 2015, Neurobiology of Disease.

[8]  R. Moratalla,et al.  Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a Calcium-Binding Protein, Reduces L-DOPA-Induced Dyskinesias in Mice , 2015, Biological Psychiatry.

[9]  P. Lewitt,et al.  Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.

[10]  Joshua L. Plotkin,et al.  Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia , 2014, Nature Communications.

[11]  P. Cowen,et al.  Tyrosine-free amino acid mixtures reduce physiologically-evoked release of dopamine in a selective and activity-dependent manner , 2014, Journal of psychopharmacology.

[12]  R. Moratalla,et al.  L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice , 2014, Biological Psychiatry.

[13]  R. Moratalla,et al.  Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease , 2014, Neurobiology of Disease.

[14]  Lei Zhang,et al.  Change in Plasma Levels of Amino Acid Neurotransmitters and its Correlation with Clinical Heterogeneity in Early Parkinson's Disease Patients , 2013, CNS neuroscience & therapeutics.

[15]  D. Dexter,et al.  Parkinson disease: from pathology to molecular disease mechanisms. , 2013, Free radical biology & medicine.

[16]  R. Moratalla,et al.  Methamphetamine and Parkinson's Disease , 2013, Parkinson's disease.

[17]  Jun Shen.  Modeling the glutamate–glutamine neurotransmitter cycle , 2012, Front. Neuroenerg..

[18]  Eduardo D. Martín,et al.  L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function , 2012, Neurobiology of Disease.

[19]  S. Dunnett,et al.  Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites , 2012, Behavioural Brain Research.

[20]  M. Cenci,et al.  In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels , 2012, Neurobiology of Disease.

[21]  S. Dunnett,et al.  Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: Predicting l-DOPA-induced dyskinesia , 2012, Behavioural Brain Research.

[22]  P. Calabresi,et al.  Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia , 2011, Experimental Neurology.

[23]  M. Morari,et al.  Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.

[24]  R. Moratalla,et al.  Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation , 2011, Front. Neuroanat..

[25]  D. Erlij,et al.  l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata , 2011, Neurobiology of Disease.

[26]  V. Durkalski,et al.  Relationships between large neutral amino acid levels in plasma, cerebrospinal fluid, brain microdialysate and brain tissue in the rat , 2010, Brain Research.

[27]  U. Ungerstedt,et al.  The rotational model and microdialysis: Significance for dopamine signalling, clinical studies, and beyond , 2010, Progress in Neurobiology.

[28]  R. Moratalla,et al.  Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation , 2009, Biological Psychiatry.

[29]  D. Centonze,et al.  d-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801 , 2008, The Journal of Neuroscience.

[30]  M. L. de Ceballos,et al.  Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by l‐DOPA , 2008, The European journal of neuroscience.

[31]  H. Haas,et al.  GABAA‐receptor modification in taurine transporter knockout mice causes striatal disinhibition , 2007, The Journal of physiology.

[32]  R. Moratalla,et al.  Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D1 dopamine receptors , 2007, Journal of neuroscience research.

[33]  Gonzalo Flores,et al.  Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6‐OHDA‐rat model of Parkinson's disease , 2007, Synapse.

[34]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[35]  A. Schousboe,et al.  The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer , 2006, Journal of neurochemistry.

[36]  N. Pavón,et al.  ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, Biological Psychiatry.

[37]  J. Clements,et al.  Comparison of Taurine- and Glycine-induced Conformational Changes in the M2-M3 Domain of the Glycine Receptor* , 2004, Journal of Biological Chemistry.

[38]  S. Engelborghs,et al.  Amino Acids and Biogenic Amines in Cerebrospinal Fluid of Patients with Parkinson's Disease , 2003, Neurochemical Research.

[39]  L. Denoroy,et al.  Glutamate and aspartate do not exhibit the same changes in their extracellular concentrations in the rat striatum after N‐methyl‐D‐aspartate local administration , 2003, Journal of neuroscience research.

[40]  H. Haas,et al.  Long‐lasting enhancement of corticostriatal neurotransmission by taurine , 2002, The European journal of neuroscience.

[41]  H. Haas,et al.  Expression and function of glycine receptors in striatal cholinergic interneurons from rat and mouse , 2001, Neuroscience.

[42]  A. El Idrissi,et al.  Growth Factors and Taurine Protect against Excitotoxicity by Stabilizing Calcium Homeostasis and Energy Metabolism , 1999, The Journal of Neuroscience.

[43]  T. Hökfelt,et al.  EVIDENCE FOR ASPARTATE-IMMUNOREACTIVE NEURONS IN THE NEOSTRIATUM OF THE RAT: MODULATION BY THE MESENCEPHALIC DOPAMINE PATHWAY VIA D1-SUBTYPE OF RECEPTOR , 1996, Neuroscience.

[44]  W. Benzing,et al.  Striatal glutamic acid decarboxylase immunoreactivity is increased after dopaminergic deafferentation: densitometric analysis , 1991, Neuroscience Letters.

[45]  U. Ungerstedt,et al.  Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons , 1990, Neuroscience Letters.

[46]  T. Halonen,et al.  Free amino acids in the brain of patients with Parkinson's disease , 1988, Neuroscience Letters.

[47]  U. Ungerstedt,et al.  Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis , 1986, Brain Research.

[48]  Y. Mizuno,et al.  Changes in γ-aminobutyrate, glutamate, aspartate, glycine, and taurine contents in the striatum after unilateral nigrostriatal lesions in rats , 1986, Experimental Neurology.

[49]  M. Mena,et al.  Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method , 1984, Acta neurologica Scandinavica.

[50]  U. Ungerstedt,et al.  Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. , 1984, European journal of pharmacology.

[51]  F. Guimarães,et al.  Counteraction by Nitric Oxide Synthase Inhibitor of Neurochemical Alterations of Dopaminergic System in 6-OHDA-Lesioned Rats Under l-DOPA Treatment , 2013, Neurotoxicity Research.

[52]  Eduardo D. Martín,et al.  D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. , 2008, Cerebral cortex.